Effect of obesity on declining beta cell function after diagnosis of type 2 diabetes

A possible link suggested by cross-sectional analysis

Yoshifumi Saisho, Kumiko Tanaka, Takayuki Abe, Akira Shimada, Toshihide Kawai, Hiroshi Itoh

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

It has been reported that beta cell function progressively declines in patients with type 2 diabetes. The objective of this study was to assess the effect of obesity on declining beta cell function after diagnosis of type 2 diabetes. We conducted a cross-sectional study of 689 consecutive subjects with type 2 diabetes who were admitted to our hospital from 2000 to 2007. Fasting and postprandial serum C-peptide immunoreactivity (CPR) and urinary CPR levels had been measured during admission. The subjects were stratified according to BMI and time since diagnosis. CPR index was calculated as CPR (ng/mL) / plasma glucose (mg/dL) x 100. All CPR measurements were significantly higher in the 263 obese (BMI ≥25) subjects compared to the 426 lean subjects (BMI <25). There was a significant negative correlation between CPR indices and duration of diabetes, suggesting a progressive decline in beta cell function after diagnosis of type 2 diabetes. However, this decline was more apparent in obese subjects (postprandial CPR index 0.059/year) compared to lean subjects (0.025/year). The significant difference in serum CPR indices between the lean and obese subjects was lost in subjects more than 10 years after diagnosis. In conclusion, our observations suggest that beta cell function shows a greater progressive decline in obese subjects than in lean subjects with type 2 diabetes. Treatment of obesity may be an important strategy to preserve beta cell function in patients with type 2 diabetes.

Original languageEnglish
Pages (from-to)187-195
Number of pages9
JournalEndocrine Journal
Volume59
Issue number3
DOIs
Publication statusPublished - 2012

Fingerprint

C-Peptide
Type 2 Diabetes Mellitus
Obesity
Cross-Sectional Studies
Serum
Fasting
Glucose

Keywords

  • Beta cell function
  • C-peptide
  • Obesity
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of obesity on declining beta cell function after diagnosis of type 2 diabetes : A possible link suggested by cross-sectional analysis. / Saisho, Yoshifumi; Tanaka, Kumiko; Abe, Takayuki; Shimada, Akira; Kawai, Toshihide; Itoh, Hiroshi.

In: Endocrine Journal, Vol. 59, No. 3, 2012, p. 187-195.

Research output: Contribution to journalArticle

@article{7e82c9bd9b9546ba9aaa53832d9d6eae,
title = "Effect of obesity on declining beta cell function after diagnosis of type 2 diabetes: A possible link suggested by cross-sectional analysis",
abstract = "It has been reported that beta cell function progressively declines in patients with type 2 diabetes. The objective of this study was to assess the effect of obesity on declining beta cell function after diagnosis of type 2 diabetes. We conducted a cross-sectional study of 689 consecutive subjects with type 2 diabetes who were admitted to our hospital from 2000 to 2007. Fasting and postprandial serum C-peptide immunoreactivity (CPR) and urinary CPR levels had been measured during admission. The subjects were stratified according to BMI and time since diagnosis. CPR index was calculated as CPR (ng/mL) / plasma glucose (mg/dL) x 100. All CPR measurements were significantly higher in the 263 obese (BMI ≥25) subjects compared to the 426 lean subjects (BMI <25). There was a significant negative correlation between CPR indices and duration of diabetes, suggesting a progressive decline in beta cell function after diagnosis of type 2 diabetes. However, this decline was more apparent in obese subjects (postprandial CPR index 0.059/year) compared to lean subjects (0.025/year). The significant difference in serum CPR indices between the lean and obese subjects was lost in subjects more than 10 years after diagnosis. In conclusion, our observations suggest that beta cell function shows a greater progressive decline in obese subjects than in lean subjects with type 2 diabetes. Treatment of obesity may be an important strategy to preserve beta cell function in patients with type 2 diabetes.",
keywords = "Beta cell function, C-peptide, Obesity, Type 2 diabetes",
author = "Yoshifumi Saisho and Kumiko Tanaka and Takayuki Abe and Akira Shimada and Toshihide Kawai and Hiroshi Itoh",
year = "2012",
doi = "10.1507/endocrj.EJ11-0206",
language = "English",
volume = "59",
pages = "187--195",
journal = "Endocrine Journal",
issn = "0918-8959",
publisher = "Japan Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Effect of obesity on declining beta cell function after diagnosis of type 2 diabetes

T2 - A possible link suggested by cross-sectional analysis

AU - Saisho, Yoshifumi

AU - Tanaka, Kumiko

AU - Abe, Takayuki

AU - Shimada, Akira

AU - Kawai, Toshihide

AU - Itoh, Hiroshi

PY - 2012

Y1 - 2012

N2 - It has been reported that beta cell function progressively declines in patients with type 2 diabetes. The objective of this study was to assess the effect of obesity on declining beta cell function after diagnosis of type 2 diabetes. We conducted a cross-sectional study of 689 consecutive subjects with type 2 diabetes who were admitted to our hospital from 2000 to 2007. Fasting and postprandial serum C-peptide immunoreactivity (CPR) and urinary CPR levels had been measured during admission. The subjects were stratified according to BMI and time since diagnosis. CPR index was calculated as CPR (ng/mL) / plasma glucose (mg/dL) x 100. All CPR measurements were significantly higher in the 263 obese (BMI ≥25) subjects compared to the 426 lean subjects (BMI <25). There was a significant negative correlation between CPR indices and duration of diabetes, suggesting a progressive decline in beta cell function after diagnosis of type 2 diabetes. However, this decline was more apparent in obese subjects (postprandial CPR index 0.059/year) compared to lean subjects (0.025/year). The significant difference in serum CPR indices between the lean and obese subjects was lost in subjects more than 10 years after diagnosis. In conclusion, our observations suggest that beta cell function shows a greater progressive decline in obese subjects than in lean subjects with type 2 diabetes. Treatment of obesity may be an important strategy to preserve beta cell function in patients with type 2 diabetes.

AB - It has been reported that beta cell function progressively declines in patients with type 2 diabetes. The objective of this study was to assess the effect of obesity on declining beta cell function after diagnosis of type 2 diabetes. We conducted a cross-sectional study of 689 consecutive subjects with type 2 diabetes who were admitted to our hospital from 2000 to 2007. Fasting and postprandial serum C-peptide immunoreactivity (CPR) and urinary CPR levels had been measured during admission. The subjects were stratified according to BMI and time since diagnosis. CPR index was calculated as CPR (ng/mL) / plasma glucose (mg/dL) x 100. All CPR measurements were significantly higher in the 263 obese (BMI ≥25) subjects compared to the 426 lean subjects (BMI <25). There was a significant negative correlation between CPR indices and duration of diabetes, suggesting a progressive decline in beta cell function after diagnosis of type 2 diabetes. However, this decline was more apparent in obese subjects (postprandial CPR index 0.059/year) compared to lean subjects (0.025/year). The significant difference in serum CPR indices between the lean and obese subjects was lost in subjects more than 10 years after diagnosis. In conclusion, our observations suggest that beta cell function shows a greater progressive decline in obese subjects than in lean subjects with type 2 diabetes. Treatment of obesity may be an important strategy to preserve beta cell function in patients with type 2 diabetes.

KW - Beta cell function

KW - C-peptide

KW - Obesity

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84859045371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859045371&partnerID=8YFLogxK

U2 - 10.1507/endocrj.EJ11-0206

DO - 10.1507/endocrj.EJ11-0206

M3 - Article

VL - 59

SP - 187

EP - 195

JO - Endocrine Journal

JF - Endocrine Journal

SN - 0918-8959

IS - 3

ER -